Liveome, a subsidiary of Medytox, said that it successfully attracted 7 billion won ($5.6 million) Series A funding from Lindeman Asia Investment Group.Liveome is a microbiological research-based drug development company established in 2021 after licensing live biotherapeutic product (LBP) candidate
AbbVie released a high dose of Skyrizi (ingredient: risankizumab), an interleukin-23 (IL-23) inhibitor.On Friday, the Ministry of Food and Drug Safety authorized the use of Skyrizi Prefilled Syringe 150mg and Prefilled Pen 150mg to treat adults with moderate to severe plaque psoriasis.Skyrizi 150mg
Over the past two years, terms like virus, bacteria, vaccine, bio, and microbiome have become household words both here and abroad. So it seems timely for the nation to host an international industrial expo to turn these areas into new industries of the post-Covid-19 era.“The 2022 International Viru
SK Bioscience said that it has secured excellent phase 3 clinical results for GBP510, its Covid-19 vaccine.SK Bioscience conducted phase 3 clinical trials in 4,037 adults over 18 at 16 clinical institutions in Korea, including Korea University Guro Hospital, and five overseas countries -- Thailand,
Daewoong Pharmaceutical said it completed a phase 3 clinical trial of Nabota, a botulinum toxin treatment, aimed to win indication for benign masseter hypertrophy, and applied for a marketing license of Nabota.On Thursday, the company said it applied to the Ministry of Food and Drug Safety for addin
Samsung Biologics said Wednesday that it officially incorporated Samsung Bioepis as a wholly-owned subsidiary.The announcement follows Samsung Biologics completing its first payment of the $1 billion to Biogen regarding the acquisition of Samsung Bioepis.Biogen had owned 50 percent minus one share i
SK Bioscience is likely to name its experimental Covid-19 vaccine (GBP510) “SKY Covione,” a patent information service site showed.The product's name draws particular attention because it will become if authorized by the Ministry of Food and Drug Safety, the nation’s 35th novel drug and the first ho
GI Innovation said Thursday that it has submitted a preliminary application to be listed on the secondary Kosdaq market.The lead organizers are NH Investment & Securities and Hana Financial Investment, and the associated listed organizer is Samsung Securities.The company stressed that the applicatio
SK Chemicals said it would start joint research on innovative new drugs with Oncobix, a synthetic new drug developer.Under the accord, Oncobix will derive new drug candidates and conduct synthesis research based on TOPFOMICS, its drug development platform. In addition, SK Chemicals will conduct gene
LG Chem said its Chinese partner company Transthera Bioscience obtained the Chinese National Medical Products Administration (NMPA)’s authorization to conduct a phase 2 trial of LC510255, an autoimmune disease treatment in patients with atopic dermatitis.In April last year, LG Chem signed a licensin
Boryung Pharmaceutical said it would open the first Care In Space (CIS) Challenge, a global competition event to find technologies and solutions for human health in space.Boryung leads the CIS challenge in collaboration with Axiom Space, an American human spaceflight services provider, and Starbust,
GC Cell said that it acquired a 100 percent stake in BioCentriq, an American cell and gene therapy contract development and manufacturing organization (CDMO) company, together with GC.The acquisition follows the merger completion of GC Cell and GC Labcell last November.BioCentriq, a subsidiary of th
Eliquis (ingredient: apixaban), sold by BMS and Pfizer, recently added cancer-associated venous thromboembolism (VTE) treatment in approval conditions, the government said.The Ministry of Food and Drug Safety changed the clause of the “precautions for use” in approval conditions for Eliquis late las
Bridge Biotherapeutics said it signed an exclusive license-in agreement with Shaperon for its GPCR19 (G protein-coupled receptor 19) agonist, coded BBT-209, to develop a novel therapy for idiopathic pulmonary fibrosis (IPF).Under the accord, Bridge Bio will make an upfront payment of about 2 billion
Hugel said it obtained a product license for Persnica, a hyaluronic acid (HA) filler, from China’s National Medical Products Administration (NMPA) last Friday.According to the company, the global non-surgical-centered medical aesthetics industry continues to grow rapidly. China is showing particular
Daewoong Pharmaceutical is soon to apply for a phase 2 trial of DWN12088, a pulmonary fibrosis treatment, in the U.S.Daewoong aims to develop it as the nation’s next novel medicine, after fexuprazan and enavogliflozin.On Tuesday, industry sources said that Daewoong planned to submit an Investigation
Huinno said it signed a distribution contract with Yuhan Corp. for Memo Patch, an electrocardiogram monitoring service, in Korea.The accord follows the Ministry of Health and Welfare's recent amendment to reimbursement regulations, which increased the insurance coverage of Holter Monitoring for ECG
Edwards Lifesciences Korea said Monday that it has appointed Kwon Chang-seop, the head of the clinical care and vascular business unit, as its new CEO.Kwon is a financial planning and business development expert with more than 20 years of experience in the pharmaceutical industry, including MSD Kore
Despite the outward growth of the Korean biopharmaceutical industry, it has yet to develop new global blockbuster drugs.An expert has stressed that the sector could realize such goals only when it strengthens cooperation between bio clusters, develops more sophisticated regulatory systems, and inves
Human epidermal growth factor receptor (HER) 2 inhibitors, known to be effective in treating brain metastasis in HER2 positive breast cancer, are expected to compete in the Korean market in earnest.On Thursday, the Ministry of Food and Drug Safety approved a phase 3 HER2CLIMB-05 study of Tukysa (tuc